Close Menu

AACR

During an American Association for Cancer Research session, a quartet of investigators from the US, Australia, and UK discussed ways in which gene- and pathway-based analyses can be used to gain additional functional insights from genome-wide association study data.

The microfluidic chip, called the On-Q-ity Circulating Cancer Capture and Characterization Chip, or C5, uses both antibody affinity and size to filter CTCs from normal blood. In a study comparing C5 and a chip using antibody affinity alone, On-Q-ity's dual capture chip "greatly improved" capture rate over the comparator.

As part of the TARGET initiative, researchers from the Broad Institute and collaborators at the Children's Hospital of Pennsylvania have sequenced and analyzed 81 matched tumor-normal samples from children with neuroblastoma.

The multi-partner non-profit cancer research initiative has funded new high-risk, high-reward grants using exome sequencing, genomic analysis, and tumor-specific drug response studies.

At the American Association for Cancer Research annual meeting this week, Washington University's Elaine Mardis discussed ways in which whole genome sequencing and analyses and clinical trials are complementing one another.

The findings suggest that it is feasible to use Exiqon's test to distinguish early-stage colorectal cancer patients from healthy subjects using a single plasma sample comprising less than 1 mL of blood.

In the study, Amgen researchers and academic collaborators used the Roche 454 Life Sciences platform to sequence nine genes in 320 tumor samples from a clinical trial of the EGFR inhibitor Vectibix. It represents one of the first applications of next-gen sequencing to characterize samples from a clinical trial.

At the American Association for Cancer Research annual meeting, National Institutes of Health Director Francis Collins and National Cancer Institute Director John Niederhuber highlighted opportunities for researchers to translate cancer research into clinical advances.

At the American Association for Cancer Research annual meeting, Johns Hopkins University cancer researcher Bert Vogelstein spoke about driver mutation patterns being identified in coding sequences for 100 cancers.

DNA mutations and microRNA profiles of lung cancer tumors differ between patients who have smoked compared with those who haven't, a National Cancer Institute researcher reported at AACR.

Pages